Gene
DDR2
DDR2 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (5), Actionable biomarkers (3), Trial mentions (7), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention DDR2. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 1 at the structurally incomplete recent edge.
DDR2 has 7 trial mentions across 6 years. That is too few to read as a trend, so the years are listed instead.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 0 of 8,738 | 0.00% | not measured | |
| 2025 | 0 of 8,875 | 0.00% | not measured | |
| 2024 | 0 of 8,597 | 0.00% | not measured | |
| 2023 | 0 of 8,275 | 0.00% | 4 of 11,460 | 0.03% |
| 2022 | 0 of 8,285 | 0.00% | 5 of 13,598 | 0.04% |
| 2021 | 0 of 8,692 | 0.00% | 11 of 15,045 | 0.07% |
| 2020 | 0 of 7,640 | 0.00% | 4 of 14,459 | 0.03% |
| 2019 | 0 of 7,300 | 0.00% | 5 of 12,159 | 0.04% |
| 2018 | 0 of 6,927 | 0.00% | 5 of 11,854 | 0.04% |
| 2017 | 0 of 6,558 | 0.00% | 6 of 11,595 | 0.05% |
Showing 10 of 37 years.
Assay-provider ledger (5)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Promega | Reagent supplier | Analytical validation | 1 | November 08, 2021 |
| Thermo Fisher | Reagent supplier | Analytical validation | 1 | November 08, 2021 |
| Agilent Technologies | Reagent supplier | Clinical validationAnalytical validation | 1 | September 22, 2015 |
| Life Technologies | Reagent supplier | Clinical validationAnalytical validation | 1 | September 22, 2015 |
| QIAGEN | Reagent supplier | Clinical validationAnalytical validation | 1 | September 22, 2015 |
Actionable biomarkers (3)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| DDR2 (S768R) | Dasatinib | response-associated | squamous cell lung carcinoma | Cancer Genome Interpreter |
| DDR2 (S768R) | Erlotinib | response-associated | squamous cell lung carcinoma | Cancer Genome Interpreter |
| DDR2 (I638F,L239R,G253C,G774V,L63V,G505S) | Dasatinib | response-associated | squamous cell lung carcinoma | Cancer Genome Interpreter |
Trial mentions (7)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT00357786 | Trial eligibility (AACT) |
| NCT00068107 | Trial eligibility (AACT) |
| NCT01514864 | Trial eligibility (AACT) |
| NCT01744652 | Trial eligibility (AACT) |
| NCT04439305 | Trial eligibility (AACT) |
Showing 5 of 7 trial mentions.
Target-disease associations (402)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| 46,XX testicular disorder of sex development | endocrine system disease | Mouse knockout (IMPC) |
| 46,XY disorder of sex development - adrenal insufficiency due to CYP11A1 deficiency | cancer or benign tumor | Mouse knockout (IMPC) |
| 46,XY disorder of sex development due to isolated 17,20 lyase deficiency | cancer or benign tumor | Mouse knockout (IMPC) |
| 46,XY gonadal dysgenesis - motor and sensory neuropathy | cancer or benign tumor | Mouse knockout (IMPC) |
| 46,XY gonadal dysgenesis-motor and sensory neuropathy syndrome | cardiovascular disease | Mouse knockout (IMPC) |
Showing 5 of 402 associations.
Vendor sourcing (27)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The variant not observed in the gnomAD v2.1.1 dataset (PM2_M). In silico tool predictions suggest damaging effect of the variant on gene or gene product (REV... | View ClinVar record SCV002058341.1 |
| ARUP Laboratories (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The DDR2 c.2039G>T; p.Arg680Leu variant (rs765562219), to our knowledge, is not reported in the medical literature or gene specific databases. This variant i... | View ClinVar record SCV005875586.1 |
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The c.1464A>G (p.I488M) alteration is located in exon 12 (coding exon 10) of the DDR2 gene. This alteration results from a A to G substitution at nucleotide ... | View ClinVar record SCV003526666.2 |
| Baylor College of Medicine | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted without stated criteria (ClinVar)ClinVar clinical-testing submission | No supporting text recorded; see the citation. | View ClinVar record SCV001334096.1 |
| Baylor Research Institute | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | : Patients with Fabry disease participating in 00-N-0185/TKT011 or 02-N-0220/TKT015 may be eligible. No other Fabry patients will be eligible. Patients los... | View trial NCT00068107 |
Showing 5 of 27 sourcing records.
Trial-cited literature (82)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Sitravatinib in patients with solid tumors selected by molecular alterations: results from a Phase Ib study. | Future oncology (London, England) | 2024 | 1 |
| Knee Osteoarthritis: Epidemiology, Pathogenesis, and Mesenchymal Stem Cells: What Else Is New? An Update. | International journal of molecular sciences | 2023 | 293 |
| Genomic ALK alterations in primary and relapsed neuroblastoma. | British journal of cancer | 2023 | 59 |
| Pucotenlimab in patients with advanced mismatch repair-deficient or microsatellite instability-high solid tumors: A multicenter phase 2 study. | Cell reports. Medicine | 2023 | 8 |
| Impact of ramucirumab plus erlotinib on circulating cell-free DNA from patients with untreated metastatic non-small cell lung cancer with <i>EGFR</i>-activating mutations (RELAY phase 3 randomized study). | Translational lung cancer research | 2023 | 8 |
Showing 5 of 82 papers.
Protein variant mentions (21)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.D125Y | 1 | 2011 | PMID 22328973 |
| p.E262K | 1 | 2015 | PMID 25741868 |
| p.F824W | 1 | 2011 | PMID 22328973 |
| p.F866Y | 1 | 2011 | PMID 22328973 |
| p.G253S | 1 | 2011 | PMID 22328973 |
Showing 5 of 21 variants.
Literature-extracted relations (8)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| DASATINIB | Chemical | negative_correlate |
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. | 2011 |
| Neoplasms | Disease | associate |
Sitravatinib in patients with solid tumors selected by molecular alterations: results from a Phase Ib study. | 2024 |
| Squamous Cell Carcinoma of Head and Neck | Disease | associate |
Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas. | 2015 |
| Oncogene Addiction | Disease | stimulate |
Molecular biology of lung cancer. | 2013 |
| Lung Diseases | Disease | associate |
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. | 2011 |
Showing 5 of 8 relation assertions.
Organizations publishing (124)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Dana-Farber Cancer Institute | Other | 6 | 2011 to 2021 |
| Mass General Brigham | Hospital | 6 | 2013 to 2024 |
| University of Texas MD Anderson Cancer Center | manufacturer | 4 | 2012 to 2024 |
| Government of the United States of America | Government | 3 | 2016 to 2021 |
| The University of Texas System | Academic | 3 | 2014 to 2018 |
Showing 5 of 124 organizations.
Where DDR2 appears
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- pregnancy or perinatal disease
- reproductive system or breast disease
- respiratory or thoracic disease
351 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and human sample screening reference.